Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Hanwha Systems (272210) – (Correction) Change in Revenue or Operating Profit/Loss by 30% or More / 2025-02-21 Disclosures
  • [Disclosure] Samsung Electro-Mechanics (009150) – Results of Annual General Meeting of Shareholders / 2025-03-19 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – Change in Sales or Profit/Loss Structure by 30% (15% for Large Companies) or More / 2025-01-24 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | Expanding Non-IT MLCC · Substrate Mix Improvement · Earnings Trajectory / 2025-08-01 RESEARCH
  • [Disclosure] Hanwha Aerospace (012450) – Decision on Acquisition of Shares and Investment Certificates of Other Corporations (Correction) / 2024-05-22 Disclosures
  • [Disclosure] SK square (402340) – Change in Revenues or Profit/Loss Structure Exceeding 30% (15% for Large Corporations) / 2026-02-10 Semiconductors
  • [Disclosure] Jeju Semiconductor(080220) – Setting of Record Date or Closure of Register of Shareholders / 2026-05-12 Semiconductors
  • [Disclosure] SK Hynix (000660 / SKHY) – Decision on Disposal of Treasury Shares / 2026-04-22 Disclosures

[Disclosure] LEENO Industrial (058470) – Submission of Audit Report / 2026-03-18

Posted on March 18, 2026August 4, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

LEENO Industrial has submitted its Audit Report for FY2025 after receiving an ‘Unqualified’ audit opinion from Sunghyun Accounting Corporation for its separate financial statements.

📊 [Key Disclosure Details & Financial Figures]

  • Audit Opinion & External Auditor:
    • External Auditor: Sunghyun Accounting Corporation (성현회계법인)
    • Audit Opinion: Unqualified (Separate)
    • Going Concern Uncertainty Issues: Not Applicable
    • Internal Accounting Control System Adverse Opinion Issues: Not Applicable
    • Receipt Date of Audit Report: March 18, 2026
    • Consolidated Financial Statement Target: No (Separate financial statements only)
  • Separate Financial & Earnings Figures (Unit: KRW):
    • Total Assets: KRW 791,928,165,325 (approx. KRW 791.9B / Up from KRW 657.4B YoY)
    • Total Liabilities: KRW 60,709,212,955 (approx. KRW 60.7B)
    • Total Equity: KRW 731,218,952,370 (approx. KRW 731.2B)
    • Capital Stock: KRW 7,621,185,000
    • Revenue: KRW 372,534,084,608 (approx. KRW 372.5B / Up from KRW 278.2B YoY)
    • Operating Income: KRW 176,997,188,289 (approx. KRW 177.0B / Up from KRW 124.2B YoY)
    • Income Before Income Taxes: KRW 195,856,560,281 (approx. KRW 195.9B)
    • Net Income: KRW 151,960,670,406 (approx. KRW 152.0B / Up from KRW 113.3B YoY)
  • Key Risk Factors Checklist:
    • Capital Impairment Ratio: Not Applicable (Total Equity KRW 731.2B)
    • Pre-tax Continuing Operations Loss over past 3 years: Not Applicable
    • Operating Loss over past 5 years: Not Applicable
    • Impairment Loss Ratio 50%+ Status: No
  • Other Key Details: Financial statements in the submitted audit report remain subject to change during the final approval process at the Annual General Meeting of Shareholders.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of AGM Approval and Final Annual Report Filing

The company received an ‘Unqualified’ audit opinion for its FY2025 financial statements from the external auditor. Since the financial statements presented in the audit report will be submitted for final approval at the Annual General Meeting of Shareholders, verifying the final figures through the AGM voting results and the subsequent Annual Report is essential. Relevant details can be verified in the ‘Results of Annual General Meeting of Shareholders’ and the ‘Annual Report’ filed on DART.

📢 Disclaimer and Source Information

Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific security. All investment decisions and financial responsibilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Semiconductors, Disclosures

Post navigation

Previous Post: [Disclosure] ALTEOGEN (196170) – Additional Listing (Conversion of Preferred Shares into Common Shares) / 2026-03-17
Next Post: [Disclosure] Hana Micron (067310) – Submission of Audit Report / 2026-03-18

Related Posts

  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Europe Phase 3 Clinical Trial Plan Amendment Application (Part 1 & 2) / 2026-07-14 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-09-05 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Announcement / 2026-05-06 Disclosures
  • [Disclosure] Samsung Electronics (005930) – Exercise and Non-Exercise of Voting Rights by Trustee / 2026-03-20 Disclosures
  • [Disclosure] Wonik IPS (240810) – Advance Notice of Financial Results / 2025-10-30 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – Pre-announcement of Financial Results Disclosure / 2024-07-18 Disclosures
  • [Disclosure] Hana Micron (067310) – Subscription Results of Capital Increase or Equity-Linked Bonds (Voluntary Disclosure) / 2024-08-05 Semiconductors
  • [Disclosure] SK Square (402340) – Matters Related to Sustainability Report / 2026-06-30 Semiconductors
  • [Disclosure] ALTEOGEN (196170) – Resolution on Convocation of General Shareholders Meeting / 2025-03-14 Disclosures
  • [Disclosure] Celltrion (068270) – Execution of License-in Agreement for Novel Drug Candidates for Rare Autoimmune Diseases / 2025-11-04 Disclosures
  • [Disclosure] Daeduck Electronics (353200) – Resolution on Convocation of General Meeting of Shareholders / 2024-02-28 Disclosures
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03 Disclosures
  • [Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement for Human Hyaluronidase Core Technology (ALT-B4) / 2025-03-17 Disclosures
  • [Disclosure] Hana Micron (067310) – Additional Listing (Exercise of Stock Options) / 2026-07-16 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme